What is Lifesci Capital’s Forecast for OVID Q2 Earnings?

Ovid Therapeutics (NASDAQ:OVID) – Equities researchers at Lifesci Capital decreased their Q2 2026 earnings per share (EPS) estimates for Ovid Therapeutics in a note issued to investors on Wednesday, May 13th. Lifesci Capital analyst F. Brisebois now forecasts that the company will earn ($0.10) per share for the quarter, down from their prior estimate of ($0.08). The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.49) per share. Lifesci Capital also issued estimates for Ovid Therapeutics’ Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.45) EPS.

Ovid Therapeutics (NASDAQ:OVID) last announced its earnings results on Tuesday, May 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). Ovid Therapeutics had a negative return on equity of 22.51% and a negative net margin of 240.11%.

Other analysts have also issued research reports about the company. Wedbush reissued an “outperform” rating and issued a $7.00 target price on shares of Ovid Therapeutics in a research report on Wednesday, April 15th. BTIG Research reissued a “buy” rating and issued a $4.00 target price on shares of Ovid Therapeutics in a research report on Thursday, March 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ovid Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen raised Ovid Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, HC Wainwright boosted their target price on Ovid Therapeutics from $2.00 to $4.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ovid Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $5.13.

Ovid Therapeutics Price Performance

Shares of NASDAQ OVID opened at $2.80 on Friday. The firm has a market cap of $369.26 million, a price-to-earnings ratio of -9.66 and a beta of 0.18. The company has a quick ratio of 8.97, a current ratio of 10.17 and a debt-to-equity ratio of 0.06. Ovid Therapeutics has a 52-week low of $0.27 and a 52-week high of $3.11. The business’s 50 day moving average is $2.48 and its two-hundred day moving average is $1.88.

Institutional Trading of Ovid Therapeutics

A number of large investors have recently modified their holdings of OVID. RA Capital Management L.P. purchased a new stake in shares of Ovid Therapeutics during the fourth quarter worth $17,464,000. Affinity Asset Advisors LLC increased its position in shares of Ovid Therapeutics by 169.8% during the fourth quarter. Affinity Asset Advisors LLC now owns 7,150,000 shares of the company’s stock worth $11,654,000 after acquiring an additional 4,500,000 shares during the period. Eventide Asset Management LLC purchased a new stake in shares of Ovid Therapeutics during the fourth quarter worth $6,985,000. ADAR1 Capital Management LLC increased its position in shares of Ovid Therapeutics by 33,256.7% during the fourth quarter. ADAR1 Capital Management LLC now owns 4,285,000 shares of the company’s stock worth $6,985,000 after acquiring an additional 4,272,154 shares during the period. Finally, Federated Hermes Inc. purchased a new stake in shares of Ovid Therapeutics during the fourth quarter worth $5,307,000. Hedge funds and other institutional investors own 72.24% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.